Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study
Background The annual global deaths from viral hepatitis is 1.4 million. Pakistan has the second highest burden of hepatitis C in the world. There is dire need to evaluate the response of new direct acting antivirals for the treatment of hepatitis C patients in Pakistan. World Health Organization ha...
Main Authors: | Zubia Jamil, Yasir Waheed, Maryam Malik, Asghar A. Durrani |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2018-05-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/4853.pdf |
Similar Items
-
Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
by: Muhammad Ikhlaq, et al.
Published: (2018-12-01) -
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01) -
Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01) -
Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01) -
The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
by: Sung Yong Han, et al.
Published: (2021-05-01)